Suppr超能文献

阿替洛尔和倍他洛尔每日一次方案治疗重度高血压。血流动力学方面。

Treatment of severe hypertension with atenolol and betaxolol with once-daily regimens. Hemodynamic aspects.

作者信息

Chrysant S G, Chrysant C, Bal I S, Trus J, Hitchcock A

机构信息

University of Kansas, Kansas City.

出版信息

Chest. 1989 Sep;96(3):499-504. doi: 10.1378/chest.96.3.499.

Abstract

The effectiveness and safety of once-daily administration of drugs in the treatment of moderate to severe hypertension was studied. Forty men taking diuretics were randomized to atenolol (A, n = 18), 50 mg/day, or betaxolol (B, n = 22), a new B1-blocker, 20 mg/day, if their SDAP was 105 to 125 mm Hg at baseline (weeks 2 to 4). At week 6, if SDAP was greater than 95 mm Hg, minoxidil (M), 5.5 mg/day, was added. The patients were seen every two weeks to week 16 (end of drug titration) and then every four weeks to week 32. The dosages were increased to 200 mg/day for A, 80 mg/day for B, and 20 mg/day for M as needed. Physical examinations, chest x-ray films, ECGs, echocardiograms, spirometric studies, 24-h ambulatory arterial pressures (AAP), and blood chemistry analyses were done at baseline and during treatment. A and B combined with a diuretic (furosemide, F) and M decreased the arterial pressures and heart rates equally well by both clinical and AAP measurements (p less than .001). The IVS was decreased (p less than .05), whereas LVIDd, RVIDd, and cardiothoracic ratios were increased by both A and B (p less than .05, p less than .01). No changes were noted in LVPW, LVM, EF, FS, spirometric values, or blood chemistry analyses. Common side effects were weight gain, edema, and hypertrichosis. Once-daily administration of A or B in combination with F and M were effective in the treatment of moderate to severe hypertension. Although effective, prolonged use of M may lead to volume overload and cardiomegaly. The significance of these latter findings is not yet known.

摘要

研究了每日一次给药治疗中度至重度高血压的有效性和安全性。40名服用利尿剂的男性,如果其基线时(第2至4周)的收缩期动态血压(SDAP)为105至125 mmHg,则被随机分为阿替洛尔组(A组,n = 18),每日50 mg,或倍他洛尔组(B组,n = 22),一种新型β1受体阻滞剂,每日20 mg。在第6周时,如果SDAP大于95 mmHg,则加用米诺地尔(M组),每日5.5 mg。患者每两周复诊一次直至第16周(药物滴定结束),然后每四周复诊一次直至第32周。根据需要,A组剂量增至每日200 mg,B组增至每日80 mg,M组增至每日20 mg。在基线和治疗期间进行体格检查、胸部X光片、心电图、超声心动图、肺功能检查、24小时动态动脉压(AAP)和血液化学分析。通过临床和AAP测量,A组和B组联合利尿剂(呋塞米,F)以及M组降低动脉压和心率的效果相同(p <.001)。室间隔厚度降低(p <.05),而A组和B组均使左心室舒张末期内径(LVIDd)、右心室舒张末期内径(RVIDd)和心胸比率增加(p <.05,p <.01)。左心室后壁厚度(LVPW)、左心室质量(LVM)、射血分数(EF)、短轴缩短率(FS)、肺功能值或血液化学分析均无变化。常见副作用为体重增加、水肿和多毛症。每日一次给予A组或B组联合F组和M组在治疗中度至重度高血压方面有效。虽然有效,但长期使用M组可能导致容量超负荷和心脏扩大。后一发现的意义尚不清楚。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验